The lawsuit claims Natera aggressively recruited bioinformatics scientists from Guardant to “jumpstart its lagging position ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Guardant Health (GH) one of those stocks right now? By taking ...

Medical diagnostics company Guardant Health has sued rival Natera in California federal court for allegedly stealing trade ...

Scotiabank raised the firm’s price target on Guardant Health (GH) to $52 from $47 and keeps an Outperform rating on the shares. Guardant Health ...

Canaccord analyst Kyle Mikson raised the firm’s price target on Guardant Health (GH) to $60 from $42 and keeps a Buy rating on the shares. The ...

Guggenheim restated their buy rating on shares of Guardant Health (NASDAQ:GH – Free Report) in a report released on Monday ...

Guardant Health (NYSE:GH) reported fourth-quarter adjusted EPS loss of 62 cents, compared to a loss of 64 cents a year ago, ...

The oncology testing specialist reported strong top-line growth, but also rising costs and ongoing net losses.

Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift ...

Guardant Health (NASDAQ:GH – Get Free Report) had its price target increased by equities research analysts at Stifel Nicolaus ...

Guardant Health, Inc. is a precision oncology company, which engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions ...

TD Cowen analyst Dan Brennan raised the firm’s price target on Guardant Health (GH) to $56 from $42 and keeps a Buy rating on the shares. The firm said results were inline with the ...